Emerging therapies in the treatment of Clostridium difficile-associated disease

Annals of Pharmacotherapy

Volumn 40, Issue 12, 2006, Pages 2164-2169

  Jodlowski, Tomasz Z ^a,b   Oehler, Richard ^c   Kam, Linda W ^d   Melnychuk, Igor ^c  

^a ST JOHN'S UNIVERSITY   (United States)

^b JACOBI MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Clostridium difficile; Intravenous immunoglobulin; Nitazoxanide; Rifaximin; Tinidazole; Tolevamer; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; ANTIPARASITIC AGENT; ANTITOXIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CLOSTRIDIUM TOXIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MACROLIDE; METRONIDAZOLE; MONOCLONAL ANTIBODY; NITAZOXANIDE; OPT 80; POLYMER; RAFALAZIL; RAMOPLANIN; RIFAMPICIN; RIFAMPICIN DERIVATIVE; RIFAXIMIN; TIACUMICIN B; TINIDAZOLE; TOLEVAMER; TOXOID; VACCINE; VANCOMYCIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ALLERGIC REACTION; ANAPHYLAXIS; ANOREXIA; ARTHRALGIA; ARTICLE; BACTERIAL INFECTION; BITTER TASTE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; DIARRHEA; DRUG COST; DRUG INFORMATION; DRUG RESEARCH; DRUG TREATMENT FAILURE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOKALEMIA; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INTERNET; MEDICAL LITERATURE; MEDICAL SOCIETY; MEDLINE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PUBLICATION; RECURRENT INFECTION; SIDE EFFECT; THROMBOSIS; TREATMENT DURATION; TREATMENT PLANNING; VACCINATION; VOMITING;

ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; RIFAMYCINS; TINIDAZOLE; VACCINATION;

EID: 33845609225     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H340     Document Type: Article

References (40)

1. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ 2004;171:51-8.
2. Owens RC. Clostridium difficile-associated disease: an emerging threat to patient safety. Pharmacotherapy 2006;26:299-311.
3. Aslam S, Hamill R, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005;5:549-57.
4. Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case control studies. CMAJ 2004;171:33-8.
5. Dial S, Delaney J, Berkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294:2989-95.
6. O'Mara NB. Severe infections caused by Clostridium difficile-a growing problem. Pharmacist Letter 2006;22(1):220108.
7. Feteky R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol 1997;92:739-50.
8. Malnick SD, Zimhony O. Treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother 2002;36:1767-75. DOI 10.1345/aph.1A160
9. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association and gatifloxacin use. Clin Infect Dis 2004;38:640-5.
10. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-41.
11. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9.
12. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40:1586-90.
13. Young GP, Ward PB, Bayley N, et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 1985;89:1038-45.
14. Gerard L, Garey KW, Dupont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 2005;3:201-11.
15. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005;51(suppl 1):36-66.
16. Boero M, Berti E, Morgando A, et al. Treatment for colitis caused by Clostridium difficile: results of a randomized, open-label study of rifaximin vs vancomycin. Microbiol Medica 1990;5:74-7.
17. Fox LM, Saravolatz LD. Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 2005;40:1173-80.
18. McVay CS, Rolfe RD. In vitro and in vivo activities of nitazoxanide agents against Clostridium difficile. Antimicrob Agents Chemother 2000;44:2254-8.
19. Dubreuil L, Houcke I, Mouton Y, et al. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother 1996;40:2266-70.
20. Melgarejo NA, Musher DM, Logan N, et al. The emerging problem of metronidazole failure in Clostridium difficile colitis (CDC) and the response to treatment with nitazoxanide (NTX) (abstract 319). Presented at: 43rd Meeting of Infectious Diseases Society of America, San Francisco, October 6-9, 2005.
21. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006;43:421-7.
22. Leung DY, Kelly CP, Boguniewicz, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991;118:633-7.
23. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 2004;53:882-4.
24. McPherson S, Rees CJ, Ellis R, et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006;49:1-6.
25. Murphy C, Vernon M, Cullen M. Intravenous immunoglobulin for resistant Clostridium difficile infection. Age Ageing 2006;35:85-6.
26. Drug topics red book. Montvale, NJ: Thomson PDR, 2006.
27. Fung HB, Doan T. Tinidazole: a nitroimidazole antiprotozoal agent. Clin Ther 2005;27:1859-84.
28. Jokipii AN, Jokipii L. Comparative activity of metronidazole and tinidazole against Clostridium difficile and Peptostreptococcus anaerobius. Antimicrob Agents Chemother 1987;31:183-6.
29. Louie TJ, Peppe J, Watt K, et al. Tolevamer, a novel nonantibiotic polymer compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006;43:411-20.
30. Braunlin W, Xu Q, Hook P, et al. Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Biophysical J 2004;87:534-9.
31. Genzyme announces start of Phase 3 study of novel, non-antibiotic therapy for C. difficile associated diarrhea, http://prnewswire.com (accessed 2006 Apr 4).
32. Genzyme announces positive results from phase 2 C. difficile trial. http://prnewswire.com (accessed 2006 Mar 20).
33. Tolevamer: a novel, non-antibiotic being investigated for the treatment of the most common cause of nosocomial diarrhea. www.genzyme.com/corp/Licensing/ genz_pdf_tolevamer_nonconfidential.pdf (accessed 2006 Apr 18).
34. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;342:390-7.
35. Swanson RN, Hardy DJ, Shipkowitz NL, et al. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob Agents Chemother 1991;35:1108-11.
36. Kouoff K, Wassermann S, Losonsky G, et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001;69:988-95.
37. Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001;357:189-93.
38. Sougioultzis S, Kyne L, Drudy D, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005;128:764-70.
39. Aboudola S, Kotloff KL, Kyne L, et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 2003;71:1608-10.
40. Bartlett JG. New drugs for Clostridium difficile infection. Clin Infect Dis 2006;43:428-31.